Century Therapeutics (IPSC) Non Operating Income (2022 - 2026)

Century Therapeutics (IPSC) has 5 years of Non Operating Income data on file, last reported at $2.0 million in Q1 2026.

• On a quarterly basis, Non Operating Income fell 14.47% year-over-year to $2.0 million in Q1 2026; TTM through Mar 2026 was $7.3 million, a 41.77% decrease from a year earlier, with the FY2025 full-year figure at $7.6 million, down 42.96% from the prior year.
• Non Operating Income for Q1 2026 stood at $2.0 million, up from $1.4 million in the prior quarter.
• Over the last five years, Non Operating Income for IPSC reached as high as $3.6 million in Q2 2024 and fell as low as $381000.0 in Q2 2022.
• Historically, Non Operating Income has averaged $2.4 million across 5 years, with a median of $2.3 million in 2025.
• Across the five-year window, Non Operating Income soared 618.11% in 2023 and slumped 52.73% in 2025, its largest moves.
• Year by year, Non Operating Income stood at $1.7 million in 2022, then surged by 111.05% to $3.5 million in 2023, then dropped by 14.54% to $3.0 million in 2024, then slumped by 52.73% to $1.4 million in 2025, then soared by 44.41% to $2.0 million in 2026.
• Per Business Quant data, the three most recent Non Operating Income figures were $2.0 million in Q1 2026, $1.4 million in Q4 2025, and $1.7 million in Q3 2025.